摘要
目的比较恩替卡韦与阿德福韦酯抗乙型肝炎病毒（HBV）的疗效。方法选择慢性乙型肝炎病人HBeAg阳性，HBV DNA〉10^5拷贝／mL，血清丙氨酸氨基转移酶（ALT）为正常值或正常上限的2-5倍，血清总胆红素小于正常值50％的41例病人，随机分为恩替卡韦组（20例）和阿德福韦组（21例）。治疗的wk2、wk4、wk8、wk12、wk16、wk24、wk48分别检测血清ALT、HBV DNA水平及乙型肝炎病毒血清学标志物（HBVM），并观察药物的安全性。结果恩替卡韦组在治疗wk2时HBV DNA水平下降幅度较阿德福韦组大，分别为-3．1 log10 copies／mL与-2.2 log10 copies／mL，ALT复常率分别为85％与76％，均高于阿德福韦组；恩替卡韦与阿德福韦酯治疗后，血清HBeAg阴转率、HBeAg血清转换率及不良事件发生率两组相比差异无统计学意义。结论恩替卡韦治疗慢性乙型肝炎HBV DNA下降幅度较阿德福韦显著，ALT复常率高，且不受ALT水平的影响。
Objective To study the anti-HBV effects of Entecavir and Adefovir. Methods 41 chronically infected HBeAg（＋） patients with HBV DNA〉10^5cp1/mL in the body, serum ALT 2-5 times higher than normal level and serum STB 2 times lower than normal level were randomly divided into Entecavir group and Adefovir group. Serum ALT, HBV DNA and HBVM were assessed at Week 2, 4, 8, 12, 16, 24, 48 and the safety of drugs were also evaluated during the treatment. Results The reduction of HBV DNA of Entecavir in serum was -3.1 log10 copies/mL and the ALT recovery rate was 85%. Both of them were higher than those in Adefovir group, which were -2.2 log10 copies/mL and 76%; there was no significant difference between two groups about the negative rate of HBeAg, the HBeAg seroconversion and the adverse event rate after the treatment. Conclusion Compared to Adefovir, the reduction of HBV DNA and the ALT recovery rate of Entecavir were higher, and the effect was not influenced by ALT.
出处
《世界感染杂志》
2007年第4期303-304,311,共3页
World Journal of Infection
